Gilead Sciences to acquire YM BioSciences

摘要

US biopharmaceutical company Gilead Sciences, Inc. and Canadian drug development company YM BioSciences Inc. have signed a definitive agreement under which Gilead will acquire YM for US$2.95 per share in cash. The transaction has received the unanimous approval of YM's Board of Directors, and values YM at approximately US$510 million, with YM reporting C$125.5 million in cash and cash equivalents as of 30 September 2012. YM Biosciences acquired Melbourne biopharmaceutical company Cytopia Pty Ltd in 2010 for approximately US$12 million.